30 completed, 4 terminated, 1 unknown, 1 withdrawn. 36 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 36 | Completed 30, Terminated 4, Unknown 1, Withdrawn 1 |
| Phase 2 | 12 | Completed 10, Terminated 2 |
Follow tipifarnib: new trials by email Literature Review of tipifarnib trials Research Report on tipifarnib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer Tipifarnib, Osimertinib - NSCLC | Phase 1 | Withdrawn | Kura Oncology, Inc. | 2023-02-01 | 2023-03-06 | |
| Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Tipifarnib, Alpelisib - HNSCC | Phase 1 / Phase 2 | Completed | Kura Oncology, Inc. | 45 | 2021-12-07 | 2026-09-08 |
| Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies Tipifarnib - Advanced Solid Tumor | Phase 1 | Terminated | Kura Oncology, Inc. | 6 | 2021-05-06 | 2023-09-21 |
| Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer tipifarnib, paclitaxel, doxorubicin - Breast Cancer, Male Breast Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2007-04-01 | 2021-02-16 |
| Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia cytarabine, daunorubicin hydrochloride, tipifarnib - Leukemia | Phase 1 | Completed | University Health Network, Toronto | 24 | 2007-04-01 | 2015-07-23 |
| Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma Bortezomib and Tipifarnib - Multiple Myeloma | Phase 1 | Completed | Emory University | 12 | 2006-12-01 | 2015-03-10 |
| Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase Bortezomib, Laboratory Biomarker Analysis, Tipifarnib - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2006-08-01 | 2015-04-15 |
| Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma sorafenib tosylate, erlotinib hydrochloride, tipifarnib - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 92 | 2006-04-01 | 2018-07-02 |
| Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia cytarabine, daunorubicin hydrochloride, etoposide - Leukemia | Phase 1 | Terminated | Ohio State University Comprehensive Cancer Center | 30 | 2006-03-01 | 2013-05-03 |
| Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer Laboratory Biomarker Analysis, Sorafenib Tosylate, Tipifarnib - Advanced Malignant Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 74 | 2005-10-01 | 2017-04-27 |
| Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer Gemcitabine Hydrochloride, Tipifarnib, Laboratory Biomarker Analysis - Recurrent Breast Carcinoma, Stage IV Breast Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 31 | 2005-09-01 | 2015-01-13 |
| A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma PS-341, R11577 - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 42 | 2005-08-01 | 2013-11-25 |
| Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma bortezomib, tipifarnib, laboratory biomarker analysis - Refractory Multiple Myeloma, Stage II Multiple Myeloma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 64 | 2005-08-01 | 2013-10-08 |
| Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia tipifarnib, etoposide - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Completed | National Cancer Institute (NCI) | 100 | 2005-03-01 | 2013-01-09 |
| Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia tipifarnib, pharmacological study, laboratory biomarker analysis - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Erythroid Leukemia (M6) | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2004-10-01 | 2013-02-04 |
| Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia cytarabine, idarubicin, tipifarnib - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 95 | 2004-09-01 | 2014-05-26 |
| Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 29 | 2004-05-20 | 2018-05-18 |
| Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma radiation therapy, tipifarnib - Untreated Childhood Brain Stem Glioma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 51 | 2004-01-01 | 2014-05-15 |
| Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer tipifarnib, radiation therapy - Pancreatic Cancer | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 18 | 2004-01-01 | 2020-04-15 |
| Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer Capecitabine, Docetaxel, Laboratory Biomarker Analysis - Adult Solid Neoplasm, Inflammatory Breast Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 53 | 2003-09-01 | 2015-05-04 |
Showing 20 of 36. Sign in to see all of them.
Leukemia, Myeloid, Acute (7) · Congenital Abnormalities (5) · Glioblastoma (5) · Leukemia (5) · Leukemia, Erythroblastic, Acute (5) · Leukemia, Megakaryoblastic, Acute (5) · Leukemia, Monocytic, Acute (5) · Leukemia, Myelomonocytic, Acute (5) · Blast Crisis (4) · Brain Neoplasms (4) · Breast Neoplasms (4) · Gliosarcoma (4) · Leukemia, Myelomonocytic, Chronic (4) · Multiple Myeloma (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4)
National Cancer Institute (NCI) (18) · Kura Oncology, Inc. (3) · Abramson Cancer Center at Penn Medicine (2) · M.D. Anderson Cancer Center (2) · City of Hope Medical Center (1) · Emory University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · NYU Langone Health (1) · National Center for Research Resources (NCRR) (1) · National Institutes of Health Clinical Center (CC) (1) · Ohio State University Comprehensive Cancer Center (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · The University of Texas Health Science Center at San Antonio (1) · University Health Network, Toronto (1) · University of Maryland, Baltimore (1)
United States (35) · Canada (3) · Australia (1)
Stephen Michael Hahn, MD (2) · Timothy Cloughesy (2) · Anthony W. Tolcher, MD (1) · Banu Arun (1) · Brigitte C. Widemann, MD (1) · Daphne Haas-Kogan (1) · Darrin Beaupre (1) · David Hong (1) · David Sommerhalder, MD (1) · Dawn Hershman (1) · Eric K. Rowinsky, MD (1) · Howard S. Hochster, MD (1) · Jeffrey Lancet (1) · Jorge Cortes (1) · Jorge E Cortes, MD (1)
PMID 15570084, PMID 15711184, PMID 16170172, PMID 16877733, PMID 19092853, PMID 19109557, PMID 20860038, PMID 23676418, PMID 24068539
N01CM62202 (3), N01CM62204 (2), P30CA015083 (2), P30CA016672 (2), U01CA062399 (2), U01CA062461 (2), U01CA062505 (2), M01RR000096 (1), N01CM17003 (1), N01CM62205 (1), N01CM62208 (1), P30CA013330 (1), P30CA033572 (1), P30CA054174 (1), P30CA076292 (1)